《业绩快报》药明康德(02359.HK)料上半年净利润按年增约62.5%至17.2亿人币
药明康德(02359.HK)公布,公司今年上半年整体营业收入预计按年增长约22.68%至72.3亿元人民币(下同),净利润预计按年增长约62.49%至17.2亿元,基本每股收益预计按年增长约63.04%。
公司指,逐步从新型冠状病毒肺炎疫情中恢复过来,并在第二季度实现强劲增长。与去年第二季度相比,公司营业收入预计按年增长约29.41%至40.4亿元,净利润预计按年增长约111.46%至14.1亿元,基本每股收益预计按年增长约110.34%。
公司提到,营业总收入在公司美国区实验室服务的收入和利润因为今年第二季美国新冠疫情加重受到较大负面影响的情况下,公司中国区实验室服务及CDMO(合同开发生产服务)服务分部已全面运营,且海外客户的需求增加。得益於强劲需求、产能利用及经营效率的提升,集团於第二季实现营业收入强劲增长。同时,集团的临床CRO(合同研究服务)及SMO(现场管理服务)服务也处於逐步恢复中。
非经常性项目方面,今年上半年,公司的非经常性项目金额较去年同期有所增长,主要是由於若干投资组合公司的市场价值上涨,使本公司投资组合产生公允价值收益约10.3亿元,而去年同期的公允价值亏损为1,825万元。其中,公司於报告期间变更对一间投资组合公司的会计核算方式,从而确认投资收益3.51亿元,惟部分被公司於去年发行的可转换债券的转换权非现金价值升值导致公允价值亏损4.87亿元所抵销。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.